Our President & CEO, Chad Costley, MD, shared insights regarding the historical development of #mucosal, specifically #intranasal vaccines, their advantages over intramuscular ones, and what the future holds for BlueWillow with @pharmasalmanac. Learn more: https://t.co/tYMzEISUhk
BlueWillow’s novel adjuvant platform has broad implications in developing nasal vaccines to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. Read about our peanut allergy program in @SnackSafely: https://t.co/PWEEohRAIj
In collaboration with Medigen, BlueWillow Biologics announces positive results for #intranasal#COVID19#booster candidate in pre-clinical studies. Learn more: https://t.co/z14vRMIH8N
“Intranasal vaccination has now reached the precipice of transforming the vaccine industry -- the long sought-after promise of protective, needle-free and inexpensive vaccination is now within our reach.”
Read more on @PharmaScrip: https://t.co/rhripA66oQ
Important article in @nytimes about the benefits of #intranasalvaccines over injections for #COVID19, but virus-based delivery is not the only solution. BlueWillow has an #intranasal adjuvant that has been proven to be safe in humans. Learn more at https://t.co/DVzbc0YzTg
Nasal vaccines may be the best way to prevent infections long term, because they provide protection exactly where it is needed to fend off the virus: the mucosal linings of the airways, where the coronavirus first lands, @apoorva_nyc writes. https://t.co/ZYDET4hXpH
BlueWillow Biologics is developing #intranasal#vaccines that enable #mucosalimmunity, the body's first line of defense, while simultaneously inducing systemic immunity. https://t.co/YeheLH0OlZ
Our President and CEO, Chad Costley, MD, shared insights regarding the benefits of #intranasal vaccines with @biospace. Check out how BlueWillow is developing the next generation of safe and effective vaccines: https://t.co/rmrtS7QhCn
As #COVID19 variants continue to emerge, there is an impending need for a solution that inhibits nasal carriage of the virus and prevents transmission.
Working with Medigen, BlueWillow continues our mission to develop an #intranasal#booster#vaccine. https://t.co/uag2iW7eaZ
We agree w @ashishkjha – as the need for global vaccinations grows, we must turn to next gen non-needle options as a potential solution. #intranasal vaccines can induce mucosal immunity & are easier-to-administer, more patient-friendly & straightforward to manufacture & transport
And last but not least
Focus on global vaccinations
Soon, the roadblock won't be vaccine doses
It'll be syringes, needles, cold storage, personnel
And lack of demand due to misinformation
We must combat all of these
And help get the world vaccinated
13/n
Interesting @STAT Pharmalot article on how the Omicron variant has emphasized the need for vaccine equity across our global community. https://t.co/Hu8xFJQ4Gv
@BlueWillowBio's #intranasal#COVID19 vaccine may strengthen the body's immune response by inducing #mucosalimmunity. https://t.co/LAjAWUGCjy
This review discusses how #nasal#vaccines can potentially serve as a booster for intramuscular vaccines. https://t.co/74iGaxe55d
A @Healthline article discusses how an #intranasal#COVID19#vaccine could make the global vaccination process both simpler and faster. https://t.co/H9IDwIBFFk
@BlueWillowBio is working with Medigen to develop S-2P-NE-01, a nasal #vaccine for SARS-CoV-2. https://t.co/hEedpzuyc1
@WSJ reports that the next generation of #COVID19#vaccines could come in #nasal spray form, which can accommodate global vaccination efforts. https://t.co/1GIBYe3a8X
We couldn't agree more - we are developing S-2P-NE-01, a nasal #vaccine for SARS-CoV-2. https://t.co/hEedpzuyc1
This @qz article discusses how inhaled nasal vaccines can become the future of inoculation due to potential ease of access and use as well as increased effectiveness. https://t.co/KBQALGsCu4
A review published in @tandfonline's Human Vaccines & Immunotherapeutics explores approaches to an effective #mucosal#vaccine formulation, which can potentially induce long-lasting systemic and #mucosalimmunity to confer protection against #COVID19. https://t.co/3DHze9MAug
On @GMA, @DrJAshton sheds light on the potential benefits of #COVID19#intranasal#vaccines. "There is a #mucosalimmunity that can be generated via a nasal spray vaccination method that also has the potential for reducing transmission." https://t.co/V9cxBa8yVM"
Check out this opinion piece from @sciam that discusses the potential advantages of stopping the spread of #COVID19 using #nasal#vaccines. https://t.co/vSdvMrPjK6